Influenza Virus : Clinical Features, Complications and Laboratory
Diagnosis
Influenza is a single-stranded, helically shaped, RNA virus of the
orthomyxovirus family. Basic antigen types A, B, and C are determined by
the nuclear material. Type A influenza has subtypes that are determined by
the surface antigens hemagglutinin (H) and neuraminidase (N). Three types
of hemagglutinin in humans (H1, H2, and H3) have a role in virus attachment
to cells. Two types of neuraminidase (N1 and N2) have a role in virus
penetration into cells.
Influenza A causes moderate to severe illness and affects all age groups.
The virus infects humans and other animals. Influenza A viruses are
perpetuated in nature by wild birds, predominantly waterfowl. Most of these
viruses are not pathogenic to their natural hosts and do not change or
evolve. Influenza B generally causes milder disease than type A and
primarily affects children. Influenza B is more stable than influenza A,
with less antigenic drift and consequent immunologic stability. It affects
only humans. Influenza C is rarely reported as a cause of human illness,
probably because most cases are subclinical. It has not been associated
with epidemic disease.
The nomenclature to describe the type of influenza virus is expressed in
this order: 1) virus type, 2) geographic origin where it was first
isolated, 3) strain number, 4) year of isolation, and 5) virus subtype.
Pathogenesis
Following respiratory transmission, the virus attaches to and penetrates
respiratory epithelial cells in the trachea and bronchi. Viral replication
occurs, which results in the destruction of the host cell. Viremia has
rarely been documented. Virus is shed in respiratory secretions for 5–10
days.
Clinical Features
The incubation period for influenza is usually 2 days, but can vary from 1
to 4 days. Influenza illness can vary from asymptomatic infection to
severe. In general, only about 50% of infected persons will develop the
classic clinical symptoms of influenza.
“Classic” influenza disease is characterized by the abrupt onset of fever,
myalgia, sore throat, nonproductive cough, and headache. The fever is
usually 101°–102°F, and accompanied by prostration (bedridden). The onset
of fever is often so abrupt that the exact hour is recalled by the patient.
Myalgias mainly affect the back muscles. Cough is believed to be a result
of tracheal epithelial destruction. Additional symptoms may include
rhinorrhea (runny nose), headache, substernal chest burning and ocular
symptoms (e.g., eye pain and sensitivity to light).
Systemic symptoms and fever usually last from 2 to 3 days, rarely more than
5 days. They may be decreased by such medications as aspirin or
acetaminophen. Aspirin should not be used for infants, children, or
teenagers because they may be at risk for contracting Reye syndrome
following an influenza infection. Recovery is usually rapid, but some
patients may have lingering asthenia (lack of strength or energy) for
several weeks.
Complications
The most frequent complication of influenza is pneumonia, most commonly
secondary bacterial pneumonia (e.g., Streptococcus pneumoniae, Haemophilus influenzae, or Staphylococcus aureus).
Primary influenza viral pneumonia is an uncommon complication with a high
fatality rate. Reye syndrome is a complication that occurs almost
exclusively in children taking aspirin, primarily in association with
influenza B (or varicella zoster), and presents with severe vomiting and
confusion, which may progress to coma due to swelling of the brain.
Other complications include myocarditis (inflammation of the heart) and
worsening of chronic bronchitis and other chronic pulmonary diseases. Death
is reported in less than 1 per 1,000 cases. The majority of deaths
typically occur among persons 65 years of age and older.
Impact of Influenza
An increase in mortality typically accompanies an influenza epidemic.
Increased mortality results not only from influenza and pneumonia but also
from cardiopulmonary and other chronic diseases that can be exacerbated by
influenza.
The number of influenza-associated deaths varies substantially by year,
influenza virus type and subtype, and age group. In a study of influenza
seasons from 1976-77 through 2006-07, the estimated number of annual
influenza-associated deaths from respiratory and circulatory causes ranged
from a low of 3,349 (1985-86 season) to a high of 48,614 (2003-04 season),
with an average of 23,607 annual influenza-associated deaths. Persons 65
years of age and older account for approximately 90% of deaths attributed
to pneumonia and influenza. During seasons with prominent circulation of
influenza A(H3N2) viruses, 2.7 times more deaths occurred than during
seasons when A(H3N2) viruses were not prominent.
The risk for complications and hospitalizations from influenza are higher
among persons 65 years of age and older, young children, and persons of any
age with certain underlying medical conditions. An average of more than
200,000 hospitalizations per year are related to influenza, with about 37%
occurring in persons younger than 65 years. A greater number of
hospitalizations occur during years that influenza A(H3N2) is predominant.
In nursing homes, attack rates may be as high as 60%, with fatality rates
as high as 30%. The cost of a severe epidemic has been estimated to be $12
billion.
Among children 0–4 years of age, hospitalization rates have varied from 100
per 100,000 healthy children to as high as 500 per 100,000 for children
with underlying medical conditions.
Hospitalization rates for children 24
months of age and younger are comparable to rates for persons 65 and older.
Children 24-59 months of age are at less risk of hospitalization from
influenza than are younger children, but are at increased risk for
influenza-associated clinic and emergency department visits.
Healthy children 5 through 18 years of age are not at increased risk of
complications of influenza. However, children typically have the highest
attack rates during community outbreaks of influenza. They also serve as a
major source of transmission of influenza within communities. Influenza has
a substantial impact among school-aged children and their contacts. These
impacts include school absenteeism, medical care visits, and parental work
loss. Studies have documented 5 to 7 influenza-related outpatient visits
per 100 children annually, and these children frequently receive
antibiotics.
Laboratory Diagnosis
The diagnosis of influenza is usually suspected on the basis of
characteristic clinical findings, particularly if influenza has been
reported in the community.
Virus can be isolated from throat and nasopharyngeal swabs obtained within
3 days of onset of illness. Culture is performed by inoculation of the
amniotic or allantoic sac of chick embryos or certain cell cultures that
support viral replication. A minimum of 48 hours is required to demonstrate
virus, and 1 to 2 additional days to identify the virus type. As a result,
culture is helpful in defining the etiology of local epidemics, but not in
individual case management.
Serologic confirmation of influenza requires demonstration of a
significant rise in influenza IgG. The acute-phase specimen should be taken
less than 5 days from onset, and a convalescent specimen taken 10–21 days
(preferably 21 days) following onset. Complement fixation (CF) and
hemagglutination inhibition (HI) are the serologic tests most commonly
used. The key test is HI, which depends on the ability of the virus to
agglutinate erythrocytes and inhibition of this process by specific
antibody.
Diagnosis requires at least a fourfold rise in antibody titer.
Rapid diagnostic testing for influenza antigen is available, but because
these tests fail to detect many patients with influenza, CDC recommends
antiviral treatment with oseltamivir or zanamivir as early as possible for
patients with confirmed or suspected influenza who have severe,
complicated, or progressive illness; who require hospitalization; or who
are at greater risk for serious influenza-related complications.
Details about the laboratory diagnosis of influenza are available on the
CDC influenza website at
http://www.cdc.gov/flu/professionals/diagnosis/index.htm
Epidemiology
Occurrence
Influenza occurs throughout the world.
Reservoir
Humans are the only known reservoir of influenza types B and C. Influenza A
viruses may infect both humans and animals. There is no chronic carrier
state.
Transmission
Influenza is primarily transmitted from person to person via large
virus-laden droplets (particles more than 5 microns in diameter) that are
generated when infected persons cough or sneeze. These large droplets can
then settle on the mucosal surfaces of the upper respiratory tracts of
susceptible persons who are near (within 3 feet) infected persons.
Transmission may also occur through direct contact or indirect contact with
respiratory secretions such as when touching surfaces contaminated with
influenza virus and then touching the eyes, nose or mouth.
Temporal Pattern
Influenza activity peaks from December to March in temperate climates, but
may occur earlier or later. During 1982–2012, peak influenza activity in
the United States occurred most frequently in January (17% of seasons), and
February (47% of seasons). However, peak influenza activity occurred in
March, April, or May in 17% of seasons. Influenza occurs throughout the
year in tropical areas.
Communicability
Adults can transmit influenza from the day before symptom onset to
approximately 5 days after symptoms begin. Children can transmit influenza
to others for 10 or more days.
Home /
Healthy Article /
Influenza Virus : Clinical Features, Complications and Laboratory Diagnosis
Tuesday, January 8, 2019
Influenza Virus : Clinical Features, Complications and Laboratory Diagnosis
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment